Skip to main content

Table 2 Societal Recommendations for the Management of Osteoporosis

From: Endocrinology practice patterns of hypothyroidism and osteoporosis management in a U.S. tertiary academic medical center

Osteoporosis
Category AACE NOF Endocrine Society ACP
Monitoring response to treatment with DXA scanning • Every 1–2 years • Every 2 years • Every 1–3 years • Recommends against checking during the 5 years of pharmacologic therapy
Use of bone turnover markers • Consider use to assess compliance and efficacy of treatment • No recommendations • Recognizes it as an alternative way of identifying therapy response • No recommendations
Treatment choice • Alendronate, risedronate, zoledronic acid, or denosumab for high risk patients
• Teriparatide, denosumab, or zoledronic acid for high risk patients unable to tolerate oral therapy
• Raloxifene or ibandronate for patients requiring spine-specific therapy
• No specific recommendations • Alendronate, risedronate, zoledronic acid, ibandronate, or denosumab for high risk patients
• Teriparatide or abaloparatide for very high risk patients
• Alendronate, risedronate, zoledronic acid, or denosumab treatment for 5 years.
• Recommends against estrogen or raloxifene therapy